115088-06-7

Usage

Uses

Used in Bioconjugation:
SPDB is used as a crosslinker for protein-protein conjugation, enabling the covalent attachment of proteins through their thiol and amine groups. This facilitates the creation of protein complexes for various research and diagnostic purposes.
Used in Antibody Labeling:
In the field of antibody labeling, SPDB serves as a versatile reagent for attaching fluorescent or biotin tags to antibodies. This allows for the detection and tracking of specific proteins in biological systems, enhancing the capabilities of immunoassays and other analytical techniques.
Used in Research and Diagnostics:
SPDB is used as a tool in research and diagnostics for the development of assays and tests that require the specific binding or detection of target proteins. Its ability to form stable conjugates under mild conditions makes it suitable for preserving the native structure and function of proteins during the conjugation process.
Used in Pharmaceutical Development:
In the pharmaceutical industry, SPDB can be employed for the development of drug delivery systems or as a component in the creation of biologics, where specific protein targeting and modification are required for therapeutic efficacy.
Used in Biochemical Analysis:
SPDB is utilized in biochemical analysis to study protein interactions, enzyme mechanisms, and other aspects of protein biology. Its ability to form covalent bonds with proteins allows researchers to probe the structure-function relationships of proteins and their interactions with other biomolecules.

Upstream product

• 250266-79-6 4-(pyridin-2-yldisulfanyl)butanoic acid 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 2127-03-9 2,2'-dipyridyldisulphide 
• 74124-79-1 di(succinimido) carbonate 
• 1229158-84-2 C₉H₁₁NO₂S₂*C₁₂H₂₃N 

Relevant academic research and scientific papers

BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

METHOD FOR PREPARING ACTIVATED ESTERS

The invention relates to a method for preparing an activated ester of the formula (I), where R is a (C1-C6) alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, and ALK is a (C1-C6) alkylene group, said method consisting of reacting the dicyclohexylamine P1 salt and the disuccinimidyl carbonate (DSC) in a solvent in which the dicyclohexylamine salt of the N-hydroxysuccinimide P2 is precipitated. The invention also relates to products of the formula P1.

Semisynthetic Maytansine analogues for the targeted treatment of cancer

Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same

A novel desmosine derivative, which is useful for preparing a desmosine artificial antigen, has an activated, disulfide bond on the side chain at 3 or 5 position of the pyridinium ring. The derivative can combine with a polymer having thiel groups by a disulfide bond to form the effective artificial antigen.